uu.seUppsala universitets publikasjoner
Endre søk
Link to record
Permanent link

Direct link
BETA
Östlund, Olof Petter
Alternativa namn
Publikasjoner (9 av 9) Visa alla publikasjoner
Erlinge, D., Koul, S., Omerovic, E., Fröbert, O., Linder, R., Danielewicz, M., . . . James, S. (2019). Bivalirudin versus heparin monotherapy in non-ST-segment elevation myocardial infarction. European heart journal. Acute cardiovascular care., 8, 492-501, Article ID 2048872618805663.
Åpne denne publikasjonen i ny fane eller vindu >>Bivalirudin versus heparin monotherapy in non-ST-segment elevation myocardial infarction
Vise andre…
2019 (engelsk)Inngår i: European heart journal. Acute cardiovascular care., ISSN 2048-8726, Vol. 8, s. 492-501, artikkel-id 2048872618805663Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Background: The optimal anti-coagulation strategy for patients with non-ST-elevation myocardial infarction treated with percutaneous coronary intervention is unclear in contemporary clinical practice of radial access and potent P2Y12-inhibitors. The aim of this study was to investigate whether bivalirudin was superior to heparin monotherapy in patients with non-ST-elevation myocardial infarction without routine glycoprotein IIb/IIIa inhibitor use.

Methods: In a large pre-specified subgroup of the multicentre, prospective, randomised, registry-based, open-label clinical VALIDATE-SWEDEHEART trial we randomised patients with non-ST-elevation myocardial infarction undergoing percutaneous coronary intervention, treated with ticagrelor or prasugrel, to bivalirudin or heparin monotherapy with no planned use of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention. The primary endpoint was the rate of a composite of all-cause death, myocardial infarction or major bleeding within 180 days.

Results: A total of 3001 patients with non-ST-elevation myocardial infarction, were enrolled. The primary endpoint occurred in 12.1% (182 of 1503) and 12.5% (187 of 1498) of patients in the bivalirudin and heparin groups, respectively (hazard ratio of bivalirudin compared to heparin treatment 0.96, 95% confidence interval 0.78–1.18, p=0.69). The results were consistent in all major subgroups. All-cause death occurred in 2.0% versus 1.7% (hazard ratio 1.15, 0.68–1.94, p=0.61), myocardial infarction in 2.3% versus 2.5% (hazard ratio 0.91, 0.58–1.45, p=0.70), major bleeding in 8.9% versus 9.1% (hazard ratio 0.97, 0.77–1.24, p=0.82) and definite stent thrombosis in 0.3% versus 0.2% (hazard ratio 1.33, 0.30–5.93, p=0.82).

Conclusion: Bivalirudin as compared to heparin during percutaneous coronary intervention for non-ST-elevation myocardial infarction did not reduce the composite of all-cause death, myocardial infarction or major bleeding in non-ST-elevation myocardial infarction patients receiving current recommended treatments with modern P2Y12-inhibitors and predominantly radial access.

Emneord
Bivalirudin, heparin, non-ST-elevation myocardial infarction
HSV kategori
Identifikatorer
urn:nbn:se:uu:diva-374849 (URN)10.1177/2048872618805663 (DOI)000484942800002 ()30281320 (PubMedID)
Forskningsfinansiär
Swedish Heart Lung FoundationSwedish Research CouncilAstraZenecaSwedish Foundation for Strategic Research
Tilgjengelig fra: 2019-01-24 Laget: 2019-01-24 Sist oppdatert: 2019-10-15bibliografisk kontrollert
Nyström, T., James, S., Lindahl, B., Östlund, O., Erlinge, D., Herlitz, J., . . . Hofmann, R. (2019). Oxygen Therapy in Myocardial Infarction Patients With or Without Diabetes: A Predefined Subgroup Analysis From the DETO2X-AMI Trial. Diabetes Care, 42(11), 2032-2041
Åpne denne publikasjonen i ny fane eller vindu >>Oxygen Therapy in Myocardial Infarction Patients With or Without Diabetes: A Predefined Subgroup Analysis From the DETO2X-AMI Trial
Vise andre…
2019 (engelsk)Inngår i: Diabetes Care, ISSN 0149-5992, E-ISSN 1935-5548, Vol. 42, nr 11, s. 2032-2041Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

OBJECTIVE: To determine the effects of oxygen therapy in myocardial infarction (MI) patients with and without diabetes.

RESEARCH DESIGN AND METHODS: In the Determination of the Role of Oxygen in Suspected Acute Myocardial Infarction (DETO2X-AMI) trial, 6,629 normoxemic patients with suspected MI were randomized to oxygen at 6 L/min for 6-12 h or ambient air. In this prespecified analysis involving 5,010 patients with confirmed MI, 934 had known diabetes. Oxidative stress may be of particular importance in diabetes, and the primary objective was to study the effect of supplemental oxygen on the composite of all-cause death and rehospitalization with MI or heart failure (HF) at 1 year in patients with and without diabetes.

RESULTS: As expected, event rates were significantly higher in patients with diabetes compared with patients without diabetes (main composite end point: hazard ratio [HR] 1.60 [95% CI 1.32-1.93], P < 0.01). In patients with diabetes, the main composite end point occurred in 16.2% (72 of 445) allocated to oxygen as compared with 16.6% (81 of 489) allocated to ambient air (HR 0.93 [95% CI 0.67-1.27], P = 0.81). There was no statistically significant difference for the individual components of the composite end point or the rate of cardiovascular death up to 1 year. Likewise, corresponding end points in patients without diabetes were similar between the treatment groups.

CONCLUSIONS: Despite markedly higher event rates in patients with MI and diabetes, oxygen therapy did not significantly affect 1-year all-cause death, cardiovascular death, or rehospitalization with MI or HF, irrespective of underlying diabetes, in line with the results of the entire study.

sted, utgiver, år, opplag, sider
AMER DIABETES ASSOC, 2019
HSV kategori
Identifikatorer
urn:nbn:se:uu:diva-396513 (URN)10.2337/dc19-0590 (DOI)000491450200009 ()31473600 (PubMedID)
Forskningsfinansiär
Swedish Research CouncilSwedish Heart Lung FoundationStockholm County Council
Tilgjengelig fra: 2019-11-06 Laget: 2019-11-06 Sist oppdatert: 2020-01-07bibliografisk kontrollert
Sundström, J., Lind, L., Nowrouzi, S., Lytsy, P., Marttala, K., Ekman, I., . . . Östlund, O. (2019). The Precision HYpertenSIon Care (PHYSIC) study: a double-blind, randomized, repeated cross-over study. Upsala Journal of Medical Sciences, 124(1), 51-58
Åpne denne publikasjonen i ny fane eller vindu >>The Precision HYpertenSIon Care (PHYSIC) study: a double-blind, randomized, repeated cross-over study
Vise andre…
2019 (engelsk)Inngår i: Upsala Journal of Medical Sciences, ISSN 0300-9734, E-ISSN 2000-1967, Vol. 124, nr 1, s. 51-58Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

High blood pressure is the leading risk factor for premature deaths and a major cost to societies worldwide. Effective blood pressure-lowering drugs are available, but patient adherence to them is low, likely partly due to side effects. To identify patient-specific differences in treatment effects, a repeated cross-over design, where the same treatment contrasts are repeated within each patient, is needed. Such designs have been surprisingly rarely used, given the current focus on precision medicine. The Precision HYpertenSIon Care (PHYSIC) study aims to investigate if there is a consistent between-person variation in blood pressure response to the common blood pressure-lowering drug classes of a clinically relevant magnitude, given the within-person variation in blood pressure. The study will also investigate the between-person variation in side effects of the drugs. In a double-blind, randomized, repeated cross-over trial, 300 patients with mild hypertension will be treated with four blood pressure-lowering drugs (candesartan, lisinopril, amlodipine, and hydrochlorothiazide) in monotherapy, with two of the drugs repeated for each patient. If the study indicates that there is a potential for precision hypertension care, the most promising predictors of blood pressure and side effect response to the drugs will be explored, as will the potential for development of a biomarker panel to rank the suitability of blood pressure-lowering drug classes for individual patients in terms of anticipated blood pressure effects and side effects, with the ultimate goal to maximize adherence. The study follows a protocol pre-registered at ClinicalTrials.gov with the identifier NCT02774460.

Emneord
Hypertension; blood pressure; randomised clinical trial; precision medicine
HSV kategori
Identifikatorer
urn:nbn:se:uu:diva-374958 (URN)10.1080/03009734.2018.1498958 (DOI)000461811100012 ()30265168 (PubMedID)
Tilgjengelig fra: 2019-01-24 Laget: 2019-01-24 Sist oppdatert: 2020-01-07bibliografisk kontrollert
Jernberg, T., Lindahl, B., Alfredsson, J., Berglund, E., Bergstroem, O., Engstrom, A., . . . Hofmann, R. (2018). Long-Term Effects of Oxygen Therapy on Death or Hospitalization for Heart Failure in Patients With Suspected Acute Myocardial Infarction. Circulation, 138(24), 2754-2762
Åpne denne publikasjonen i ny fane eller vindu >>Long-Term Effects of Oxygen Therapy on Death or Hospitalization for Heart Failure in Patients With Suspected Acute Myocardial Infarction
Vise andre…
2018 (engelsk)Inngår i: Circulation, ISSN 0009-7322, E-ISSN 1524-4539, Vol. 138, nr 24, s. 2754-2762Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

BACKGROUND: In the DETO2X-AMI trial (Determination of the Role of Oxygen in Suspected Acute Myocardial Infarction), we compared supplemental oxygen with ambient air in normoxemic patients presenting with suspected myocardial infarction and found no significant survival benefit at 1 year. However, important secondary end points were not yet available. We now report the prespecified secondary end points cardiovascular death and the composite of all-cause death and hospitalization for heart failure. METHODS: In this pragmatic, registry-based randomized clinical trial, we used a nationwide quality registry for coronary care for trial procedures and evaluated end points through the Swedish population registry (mortality), the Swedish inpatient registry (heart failure), and cause of death registry (cardiovascular death). Patients with suspected acute myocardial infarction and oxygen saturation of >= 90% were randomly assigned to receive either supplemental oxygen at 6 L/min for 6 to 12 hours delivered by open face mask or ambient air. RESULTS: A total of 6629 patients were enrolled. Acute heart failure treatment, left ventricular systolic function assessed by echocardiography, and infarct size measured by high-sensitive cardiac troponin T were similar in the 2 groups during the hospitalization period. All-cause death or hospitalization for heart failure within 1 year after randomization occurred in 8.0% of patients assigned to oxygen and in 7.9% of patients assigned to ambient air (hazard ratio, 0.99; 95% CI, 0.84-1.18; P=0.92). During long-term follow-up (median [range], 2.1 [1.0-3.7] years), the composite end point occurred in 11.2% of patients assigned to oxygen and in 10.8% of patients assigned to ambient air (hazard ratio, 1.02; 95% CI, 0.88-1.17; P=0.84), and cardiovascular death occurred in 5.2% of patients assigned to oxygen and in 4.8% assigned to ambient air (hazard ratio, 1.07; 95% CI, 0.87-1.33; P=0.52). The results were consistent across all predefined subgroups. CONCLUSIONS: Routine use of supplemental oxygen in normoxemic patients with suspected myocardial infarction was not found to reduce the composite of all-cause mortality and hospitalization for heart failure, or cardiovascular death within 1 year or during long-term follow-up.

Emneord
death, heart failure, hospitalization, mortality, myocardial infarction, oxygen inhalation therapy, registries
HSV kategori
Identifikatorer
urn:nbn:se:uu:diva-372939 (URN)10.1161/CIRCULATIONAHA.118.036220 (DOI)000452798400006 ()
Forskningsfinansiär
Swedish Research Council, VR20130307Swedish Foundation for Strategic Research , SFF KF10-0024Swedish Heart Lung Foundation, HLF20130262Swedish Heart Lung Foundation, HLF20160688Swedish Heart Lung Foundation, HLF20170277
Tilgjengelig fra: 2019-01-10 Laget: 2019-01-10 Sist oppdatert: 2019-01-10bibliografisk kontrollert
Hofmann, R., Witt, N., Lagerqvist, B., Jernberg, T., Lindahl, B., Erlinge, D., . . . James, S. K. (2018). Oxygen therapy in ST-elevation myocardial infarction. European Heart Journal, 39(29), 2730-2739
Åpne denne publikasjonen i ny fane eller vindu >>Oxygen therapy in ST-elevation myocardial infarction
Vise andre…
2018 (engelsk)Inngår i: European Heart Journal, ISSN 0195-668X, E-ISSN 1522-9645, Vol. 39, nr 29, s. 2730-2739Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Aims

To determine whether supplemental oxygen in patients with ST-elevation myocardial infarction (STEMI) impacts on procedure-related and clinical outcomes.

Methods and results The DETermination of the role of Oxygen in suspected Acute Myocardial Infarction (DETO2X-AMI) trial randomized patients with suspected myocardial infarction (MI) to receive oxygen at 6 L/min for 6-12 h or ambient air. In this pre-specified analysis, we included only STEMI patients who underwent percutaneous coronary intervention (PCI). In total, 2807 patients were included, 1361 assigned to receive oxygen, and 1446 assigned to ambient air. The pre-specified primary composite endpoint of all-cause death, rehospitalization with MI, cardiogenic shock, or stent thrombosis at 1 year occurred in 6.3% (86 of 1361) of patients allocated to oxygen compared to 7.5% (108 of 1446) allocated to ambient air [hazard ratio (HR) 0.85, 95% confidence interval (95% CI) 0.64-1.13; P = 0.27]. There was no difference in the rate of death from any cause (HR 0.86, 95% CI 0.61-1.22; P = 0.41), rate of rehospitalization for MI (HR 0.92, 95% CI 0.57-1.48; P = 0.73), rehospitalization for cardiogenic shock (HR 1.05, 95% CI 0.21-5.22; P = 0.95), or stent thrombosis (HR 1.27, 95% CI 0.46-3.51; P = 0.64). The primary composite endpoint was consistent across all subgroups, as well as at different time points, such as during hospital stay, at 30 days and the total duration of follow-up up to 1356 days.

Conclusions Routine use of supplemental oxygen in normoxemic patients with STEMI undergoing primary PCI did not significantly affect 1-year all-cause death, rehospitalization with MI, cardiogenic shock, or stent thrombosis.

sted, utgiver, år, opplag, sider
OXFORD UNIV PRESS, 2018
Emneord
Oxygen, ST-elevation myocardial infarction, Percutaneous coronary intervention, Registry-based randomized clinical trial, Reactive oxygen species, Reperfusion injury
HSV kategori
Identifikatorer
urn:nbn:se:uu:diva-363057 (URN)10.1093/eurheartj/ehy326 (DOI)000441009100012 ()29912429 (PubMedID)
Forskningsfinansiär
Swedish Research Council, VR20130307Swedish Foundation for Strategic Research , SFF KF10-0024Swedish Heart Lung Foundation
Tilgjengelig fra: 2018-10-18 Laget: 2018-10-18 Sist oppdatert: 2019-01-21bibliografisk kontrollert
Lindholm, D., Lindbäck, J., Armstrong, P. W., Budaj, A., Cannon, C. P., Granger, C. B., . . . Wallentin, L. (2017). Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease. Journal of the American College of Cardiology, 70(7), 813-826
Åpne denne publikasjonen i ny fane eller vindu >>Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease
Vise andre…
2017 (engelsk)Inngår i: Journal of the American College of Cardiology, ISSN 0735-1097, E-ISSN 1558-3597, Vol. 70, nr 7, s. 813-826Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Background Currently, there is no generally accepted model to predict outcomes in stable coronary heart disease (CHD).Objectives This study evaluated and compared the prognostic value of biomarkers and clinical variables to develop a biomarker-based prediction model in patients with stable CHD.Methods In a prospective, randomized trial cohort of 13,164 patients with stable CHD, we analyzed several candidate biomarkers and clinical variables and used multivariable Cox regression to develop a clinical prediction model based on the most important markers. The primary outcome was cardiovascular (CV) death, but model performance was also explored for other key outcomes. It was internally bootstrap validated, and externally validated in 1,547 patients in another study.Results During a median follow-up of 3.7 years, there were 591 cases of CV death. The 3 most important biomarkers were N-terminal pro–B-type natriuretic peptide (NT-proBNP), high-sensitivity cardiac troponin T (hs-cTnT), and low-density lipoprotein cholesterol, where NT-proBNP and hs-cTnT had greater prognostic value than any other biomarker or clinical variable. The final prediction model included age (A), biomarkers (B) (NT-proBNP, hs-cTnT, and low-density lipoprotein cholesterol), and clinical variables (C) (smoking, diabetes mellitus, and peripheral arterial disease). This “ABC-CHD” model had high discriminatory ability for CV death (c-index 0.81 in derivation cohort, 0.78 in validation cohort), with adequate calibration in both cohorts.Conclusions This model provided a robust tool for the prediction of CV death in patients with stable CHD. As it is based on a small number of readily available biomarkers and clinical factors, it can be widely employed to complement clinical assessment and guide management based on CV risk. (The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial [STABILITY]; NCT00799903)

sted, utgiver, år, opplag, sider
Elsevier, 2017
Emneord
cardiac troponin, low-density lipoprotein cholesterol, N-terminal pro-B-type natriuretic peptide, risk prediction
HSV kategori
Identifikatorer
urn:nbn:se:uu:diva-327281 (URN)10.1016/j.jacc.2017.06.030 (DOI)000407028500001 ()28797349 (PubMedID)
Tilgjengelig fra: 2017-08-08 Laget: 2017-08-08 Sist oppdatert: 2017-11-23bibliografisk kontrollert
Erlinge, D., Omerovic, E., Fröbert, O., Linder, R., Danielewicz, M., Hamid, M., . . . James, S. (2017). Bivalirudin versus Heparin Monotherapy in Myocardial Infarction. New England Journal of Medicine, 377(12), 1132-1142
Åpne denne publikasjonen i ny fane eller vindu >>Bivalirudin versus Heparin Monotherapy in Myocardial Infarction
Vise andre…
2017 (engelsk)Inngår i: New England Journal of Medicine, ISSN 0028-4793, E-ISSN 1533-4406, Vol. 377, nr 12, s. 1132-1142Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

BACKGROUND The comparative efficacy of various anticoagulation strategies has not been clearly established in patients with acute myocardial infarction who are undergoing percutaneous coronary intervention (PCI) according to current practice, which includes the use of radial-artery access for PCI and administration of potent P2Y 12 inhibitors without the planned use of glycoprotein IIb/IIIa inhibitors. METHODS In this multicenter, randomized, registry-based, open-label clinical trial, we enrolled patients with either ST-segment elevation myocardial infarction (STEMI) or non-STEMI (NSTEMI) who were undergoing PCI and receiving treatment with a potent P2Y(12) inhibitor (ticagrelor, prasugrel, or cangrelor) without the planned use of glycoprotein IIb/IIIa inhibitors. The patients were randomly assigned to receive bivalirudin or heparin during PCI, which was performed predominantly with the use of radial-artery access. The primary end point was a composite of death from any cause, myocardial infarction, or major bleeding during 180 days of follow-up. RESULTS A total of 6006 patients (3005 with STEMI and 3001 with NSTEMI) were enrolled in the trial. At 180 days, a primary end-point event had occurred in 12.3% of the patients (369 of 3004) in the bivalirudin group and in 12.8% (383 of 3002) in the heparin group (hazard ratio, 0.96; 95% confidence interval [CI], 0.83 to 1.10; P = 0.54). The results were consistent between patients with STEMI and those with NSTEMI and across other major subgroups. Myocardial infarction occurred in 2.0% of the patients in the bivalirudin group and in 2.4% in the heparin group (hazard ratio, 0.84; 95% CI, 0.60 to 1.19; P = 0.33), major bleeding in 8.6% and 8.6%, respectively (hazard ratio, 1.00; 95% CI, 0.84 to 1.19; P = 0.98), definite stent thrombosis in 0.4% and 0.7%, respectively (hazard ratio, 0.54; 95% CI, 0.27 to 1.10; P = 0.09), and death in 2.9% and 2.8%, respectively (hazard ratio, 1.05; 95% CI, 0.78 to 1.41; P = 0.76). CONCLUSIONS Among patients undergoing PCI for myocardial infarction, the rate of the composite of death from any cause, myocardial infarction, or major bleeding was not lower among those who received bivalirudin than among those who received heparin monotherapy. (Funded by the Swedish Heart-Lung Foundation and others;

sted, utgiver, år, opplag, sider
MASSACHUSETTS MEDICAL SOC, 2017
HSV kategori
Identifikatorer
urn:nbn:se:uu:diva-336480 (URN)10.1056/NEJMoa1706443 (DOI)000411348500007 ()28844201 (PubMedID)
Tilgjengelig fra: 2017-12-18 Laget: 2017-12-18 Sist oppdatert: 2017-12-18bibliografisk kontrollert
Erlinge, D., Koul, S., Eriksson, P., Schersten, F., Omerovic, E., Linder, R., . . . James, S. (2016). Bivalirudin versus heparin in non-ST and ST-segment elevation myocardial infarction-a registry-based randomized clinical trial in the SWEDEHEART registry (the VALIDATE-SWEDEHEART trial). American Heart Journal, 175, 36-46
Åpne denne publikasjonen i ny fane eller vindu >>Bivalirudin versus heparin in non-ST and ST-segment elevation myocardial infarction-a registry-based randomized clinical trial in the SWEDEHEART registry (the VALIDATE-SWEDEHEART trial)
Vise andre…
2016 (engelsk)Inngår i: American Heart Journal, ISSN 0002-8703, E-ISSN 1097-6744, Vol. 175, s. 36-46Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Background The optimal anticoagulant for patients with acute coronary syndrome treated with percutaneous coronary intervention (PCI) has not been validated in current practice of radial approach and pretreatment with potent P2Y12 inhibitors. Several studies have indicated increased bleeding rate and, in some instances, even increased mortality by the routine use of heparin and glycoprotein IIb/IIIa inhibitors compared to bivalirudin. Direct comparison of bivalirudin versus heparin alone has yielded contradictory results depending on study designs. Methods/design The VALIDATE-SWEDEHEART trial is a multicenter, prospective, randomized, registry-based, controlled, and open-label clinical trial in patients with ST-segment elevation myocardial infarction (STEMI) or non-STEMI undergoing PCI pretreated with ticagrelor, prasugrel, or cangrelor. We hypothesize that bivalirudin is superior to heparin alone in reducing death, myocardial infarction, and major bleeding events at 180 days (primary end point). The trial will enroll 3,000 patients with STEMI and 3,000 patients with non-STEMI undergoing PCI. The trial will use a hybrid registry-based randomized clinical trial design where inclusion, randomization, and baseline data collection are performed using The Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies registry. The primary composite end point (death, myocardial infarction, or major bleeding events at 180 days) will be identified through active screening after 7 and 180 days and adjudicated by a blinded central end point committee. Secondary end points and long-term outcomes will be recorded from national registries. Conclusion The VALIDATE-SWEDEHEART trial is founded on a nationwide clinical registry and uses a hybrid registry-based randomized clinical trial (RRCT) design methodology to evaluate efficacy and safety of bivalirudin as compared to heparin alone for acute coronary syndrome, in a large population receiving contemporary recommended therapies including predominantly radial invasive approach and pretreatment with potent P2Y12 inhibitors.

HSV kategori
Identifikatorer
urn:nbn:se:uu:diva-298226 (URN)10.1016/j.ahj.2016.02.007 (DOI)000375655200006 ()27179722 (PubMedID)
Tilgjengelig fra: 2016-07-01 Laget: 2016-07-01 Sist oppdatert: 2017-11-28bibliografisk kontrollert
Hijazi, Z., Lindbäck, J., Östlund, O. P., Siegbahn, A., Alexander, J. H., Granger, C. B., . . . Wallentin, L. (2015). External validation of the biomarker-based ABC-stroke risk score for atrial fibrillation. Paper presented at Congress of the European-Society-of-Cardiology (ESC), AUG 29-SEP 02, 2015, London, ENGLAND. European Heart Journal, 36(Suppl. 1), 710-711
Åpne denne publikasjonen i ny fane eller vindu >>External validation of the biomarker-based ABC-stroke risk score for atrial fibrillation
Vise andre…
2015 (engelsk)Inngår i: European Heart Journal, ISSN 0195-668X, E-ISSN 1522-9645, Vol. 36, nr Suppl. 1, s. 710-711Artikkel i tidsskrift, Meeting abstract (Annet vitenskapelig) Published
HSV kategori
Identifikatorer
urn:nbn:se:uu:diva-266247 (URN)000361205105104 ()
Konferanse
Congress of the European-Society-of-Cardiology (ESC), AUG 29-SEP 02, 2015, London, ENGLAND
Merknad

Meeting Abstract: 4203

Tilgjengelig fra: 2015-11-18 Laget: 2015-11-05 Sist oppdatert: 2017-12-01bibliografisk kontrollert
Organisasjoner